|
2022
|
Invention
|
Injectable and inhalable formulations. The present invention relates to aqueous pharmaceutical fo... |
|
2021
|
Invention
|
Inhalable formulations. The present invention relates to inhalable formulations, and kits and met... |
|
|
Invention
|
Deuterated or partially deuterated n,n-dimethyltryptamine compounds. The present invention relate... |
|
|
Invention
|
Injectable formulation. Provided herein are pharmaceutical formulations, methods for their produc... |
|
|
Invention
|
Therapeutic solid dosage forms. N,NN,N-dimethyltryptamine and its deuterated analogues and pharma... |
|
|
Invention
|
Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine com... |
|
2020
|
Invention
|
Compositions and compounds for bioanalysis.
The present invention relates to compositions compri... |
|
|
Invention
|
Compounds. The present invention relates to compounds of formula I, or pharmaceutically acceptabl... |
|
|
Invention
|
Method of synthesis. The present invention relates to the synthesis of compounds of formula III f... |
|
2019
|
Invention
|
Ketamine derivatives to treat neurological or psychological diseases. The present invention descr... |
|
|
Invention
|
Ketamine derivatives to treat neurological or psychological disorders. The present invention desc... |
|
2018
|
Invention
|
Therapeutic compounds. The present invention provides a compound of Formula I, or a pharmaceutica... |
|
|
Invention
|
Solid oral dosage forms of ketamine derivatives. This invention relates to high concentration sol... |
|
|
Invention
|
Crystalline forms of hydroxynorketamine. The present invention provides novel, stable, processabl... |
|
2017
|
Invention
|
Ketamine derivatives. The present invention provides conformationally stabilized analogues of the... |
|
|
Invention
|
Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof. This invention relate... |
